Development of pegylated interferons for the treatment of chronic hepatitis C

BioDrugs

Volumn 15, Issue 7, 2001, Pages 419-429

  Kozlowski, Antoni ^a   Charles, Stephen A ^a   Harris, J Milton ^a  

^a Shearwater Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASPARAGINASE MACROGOL; MACROGOL; PEGADEMASE; PEGYLATED INTERFERON ALPHA; UNCLASSIFIED DRUG;

COMBINED IMMUNODEFICIENCY; COVALENT BOND; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HEPATITIS C; LEUKEMIA; PRIORITY JOURNAL; REVIEW;

EID: 0034871429     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115070-00001     Document Type: Review

References (46)

1. Abuchowski A, van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977; 252: 3578-81
2. Harris JM, Zalipsky S, editors. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997
3. Harris JM. Polyethylene glycol chemistry. Biotechnical and biomédical applications. New York: Plenum, 1992
4. Working PK, Newman MS, Johnson J, etal. Safety of poly(ethylene glycol) andpoly(ethyleneglycol) derivatives. In: Harris JM, Zalipsky S, editors. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997:45-59
5. Cheng TL, Wu PY, Wu MF, et al. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem 1999; 10: 520-8
6. Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sei 1994; 83: 601-6
7. Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J Immunol 1990; 144: 209-13
8. Monfardini C, Schiavon O, Caliceti P, et al. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 1995; 6: 62-9
9. Caliceti P, Schiavon O, Veronese FM. Biopharmaceutical properties of uncase conjugated to neutral and amphiphilic polymers. Bioconjug Chem 1999; 10: 638-46
10. lu. Yoshinaga Y, Harris JM. Effects of coupling chemistry on activity of a polyethylene glycol-modified enzyme. J Bioact CompPolym 1989; 4: 17-24
11. Dust JM, Fang ZH, Harris JM. Proton NMR characterization of polyethylene glycols and derivatives. Macromolecules 1990; 23: 3742-6
12. Abuchowski A, Kazo CM, Verhoest CR, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984; 7: 175-86
13. Harris JM. Synthesis of polyethylene glycol derivatives. J Macromol Sei Rev Macromol Chem Phys 1985; C25: 325-73
14. Zalipsky S, Seltzer R, Menon-Rudolph S. Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins. Biotechnol Appl Biochem 1992; 15: 100-14
15. Gilbert CW, Park-Cho M. Interferon polymer conjugates. US Patent 5,951,974, Sep. 14, 1999
16. Zalipsky S. Alkyl succinimidyl carbonates undergo Lossen rearrangement in basic buffers. Chem Commun 1998; 69-70
17. Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res 1996; 13 (7): 996-1002
18. Edwards CK. Pegylated recombinant human soluble tumor necrosis factor receptor type I (rHu-sTNF-RI): novel high-affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis 1999; 58 Suppl. 1: 173-81
19. Morpurgo M, Veronese FM, Kachensky D, et al. Preparation and characterization of poly(ethylene glycol) vinylsulfone. Bioconjug Chem 1996; 7: 363-8
20. El Tayar N, Roberts MJ, Harris JM, et al. Polyol-IFN-beta conjugates, WO 99/55377
21. Harris JM, Kozlowski A. Polyethylene glycol and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications. US Patent 5,672,662, Sep 30; 1997
22. Thorner MO, Strasburger CJ, Wu Z, et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999 Jun; 84 (6): 2098-103
23. Goffin V, Beraichtein S, Carrière O, et al. The human growth hormone antagonist B2036 does not interact with the prolactin receptor. Endocrinology 1999 Aug; 140 (8): 3853-6
24. Ross RJ, Leung KC, Maamra M, et al. Binding and functional studies with the growth hormone receptor antagonist, B2036PEG (pegvisomant). reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 2001 Apr; 86(4): 1716-23
25. Chapman. AP, AntoniwP. SpitaliM, et al. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780-3
26. Bentley MD, Harris JM, Kozlowski A. Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation. PCT US99/23536: Oct 8; 1999
27. Hershfield MS. Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In: Harris JM, Zalipsky S, editors. Poly(ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997: 145-54
28. Burnham NL. Polymers for delivering peptides and proteins. Am J Hosp Pharm 1994; 51:210-8
29. Hillman BC, Sorensen RU. Management options: SCIDS with adenosine deaminase deficiency. Ann Allergy 1994:72:395-404
30. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol 1995; 76: S228-32
31. Keating MJ. Holmes R, Lerner S, et al. L-asparaginase and PEG asparaginase - past, present, and future. Leuk Lymphoma 1993; lOSuppl.: 153-7
32. Holle LM. Pegaspargase: an alternative. Ann Pharmacother 1997; 3: 616-24
33. Olson K, Gehant R, Mukku V. et al. Preparation and characterization of poly(ethylene glycol)ylated human growth hormone antagonist. In: Harris JM. Zalipsky S, editors. Poly (ethylene glycol): chemistry and biological applications. Washington, DC: American Chemical Society, 1997: 170-81
34. Liang JT, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med2000; 132:296-305
35. McHutchison JG, Gordon SC, Schiff ER, et al, and the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronichepatitis C. N Engl J Med 1998: 339; 1485-92
36. Poynard T, Marcellin P, Lee S, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus Interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-32
37. O'Brien C, Pockros P. Reddy R, et al. A double-blind, multicenter, randomized, parallel dose-comparison study of six regimens of 5kD, linear peginterferon alfa-2a compared with Roferon-A in patients with chronic hepatitis C. Antiviral Therapy 1999; 4 Suppl. 4: 15
38. Baiion P, Spence C, Schaffer CA. et al. Pharmacological properties of five polyethylene glycol conjugates of Interferon alfa-2a. Antiviral Therapy 1999: 4 Suppl. 4: 27
39. Heathcote EJ, Shiftman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80
40. Zeuzem S, Feinman SV, Rasenack J, et al. Peginlert'eron alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72
41. Bailon P. Palleroni A, Schaffer ÇA, et al. Rational design of a potent, long-lasting form of Interferon: a 40 kDa branched polyethylene glycol-conjugated Interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001 Mar-Apr: 12 (2): 195-202
42. Algranati NE, Sy S, Modi MW. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic Hepatitis C (CHC). Hepatology 1999; 30 (4 Pt 2): 190A
43. Sulkowski MS, Reindollar R, Yu J. Pegylated interferon alfa-2a (PEGAS YS'M) and ribavirin combination therapy for chronic hepatitis C: a phase II open-label study. Gastroenterology 2000; 118 Suppl. 2:950
44. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferonalpha2b; pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000 Nov; 68 (5): 556-67
45. Trepo C, Lindsay K, Niederau C, et al. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C [abstract GS2/07]. J Hepatology 2000: 32: 29
46. Manns MP, McHutchison JG, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial. Hepatology 2000; 32 (4): 297A